4 Undervalued Health Care Technology Stocks for Monday, November 11
Discover the top 4 undervalued Health Care Technology stocks for Monday, November 11 based on AAII’s Stock Grades.Aneeqa Nadeem
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Aneeqa Nadeem
Aneeqa Nadeem
Eunice Kim
Eunice Kim
Eunice Kim
| Share Statistics | ISPC | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2.8 | $156.0 | 2% |
|
| Shares Out (Mil) | 1.4 | 42.5 | 6% |
|
| Institutional Ownership | 100.0% | 78.5% | 99% |
|
| Float (Mil) | 2.5 | 38.7 | 7% |
|
| Beta | 1.63 | 1.17 | 86% |
|
| Avg Daily Volume (000s) | 123 | 418 | 38% |
|
| Price Change (52-week) |
(97.2%) | 44.8% | 2% |
|
| Growth | ISPC | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (25.4%) | 11.8% | 2% |
|
| Net Income (5yr) | (17.4%) | 2.7% | 23% |
|
| EPS (5yr) | na | 15.5% | na |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.8%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | ISPC | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1 | $202 | 1% |
|
| Net Income (TTM) (Mil) | ($11) | ($9) | 28% |
|
| EPS (TTM) | ($21.946) | ($1.000) | 2% |
|
| Operating Cash Flow (TTM) (Mil) | ($7) | ($1) | 23% |
|
| Net Cash Flow (TTM) (Mil) | na | $3 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $18 | 12% |
|
| Enterprise Value (Q1) (Mil) | $0 | $160 | 4% |
|
| Valuation | ISPC | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.99 | 1.28 | 24% |
|
| P/E | na | 42.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 2.7 | na |
|
| Ratios | ISPC | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (108.3%) | 60.9% | 2% |
|
| Net Margin | na | (26.3%) | na |
|
| ROA | (170.1%) | (22.8%) | 3% |
|
| ROE | (968.5%) | (9.8%) | 0% |
|
| Liabilities to Assets | 76.5% | 33.3% | 72% |
|
| F-Score | 2 | 4 | 7% |
|
iSpecimen Inc. did not pass any screens on 10/9/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors